Navigation Links
Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Date:1/16/2008

SOUTH SAN FRANCISCO, Calif., Jan. 16 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated two randomized, double-blind, placebo-controlled Phase II/III clinical studies of its once- daily topical diclofenac sodium patch to treat mild to moderate pain. One of the studies, designated the "SUPPORT" (Stop Underlying Pain with a diclofenac Patch and Obtain Relief Topically) study, will assess the efficacy and safety of Cerimon's patch compared to placebo for the treatment of pain due to acute mild to moderate ankle sprains. The second study, designated the "ACTIVE" (A Clinical Trial to Investigate the effectiVEness of diclofenac pain patch) study, will assess the safety and efficacy of Cerimon's patch compared to placebo for the treatment of pain due to mild to moderate tendonitis or bursitis of the shoulder, elbow, or wrist. Each study will enroll over 300 subjects, with 50 percent of the subjects randomized to receive the diclofenac sodium patch and the other half to receive placebo.

Paul J. Sekhri, President and CEO of Cerimon Pharmaceuticals, stated, "Our diclofenac patch is designed to offer convenient, site-specific pain relief to patients with mild to moderate forms of musculoskeletal pain without systemic side effects associated with currently available oral NSAIDs. Consumers in Japan and several other countries have responded strongly to the advantages of topical diclofenac patches virtually identical to our patch, and we believe this provides an indication of the potential market demand in the U.S. Cerimon is moving its program forward aggressively to address this unmet medical need, allowing us to build a leadership position in the US pain market."

This is the second late-stage development program Cerimon commenced in the past year. In April 2007, the Company initiated a Phase IIb study of Simulect(R) (basiliximab) for moderate-to-severe steroid-refractory ulcerative colitis.

Pain Market

Musculoskel
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
2. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
3. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
6. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
7. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
10. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
11. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
(Date:12/19/2014)... -- Baptist Health Lexington is the first facility in ... Fibrillation with Electrophysiology Services (EPS) Accreditation status from the Society ... the most common cardiac arrhythmia and has become recognized as ... stroke and possible death. More than 5 million patients in ... and the numbers are rapidly increasing as the population ages. ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... plc , (LSE: SHP, Nasdaq: SHPGY ), the ... and Drug Administration (FDA) approved the use of once-daily ... for the treatment of attention deficit hyperactivity disorder (ADHD) in ... a total treatment program. The approval is based on results ...
... YORK, Feb. 28, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... the Company,s Chief Executive Officer, will be presenting at ... Conference (New York, NY)Wednesday, March 2, 201111:00am ETCowen & ... MA)Monday, March 7, 2011 4:45pm ETROTH 23rd Annual OC ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations 2
(Date:12/19/2014)... December 19, 2014 Slone ... diagnostic, personalized medicine, healthcare information technology, and laboratory ... position of Chief Operating Officer. The announcement comes ... marked by a strengthened presence in Boston and ... "Leslie lives and breathes the client experience," said ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Being in good ... researchers report. They looked at data from more than ... who underwent treadmill tests between 1991 and 2009. Those ... chance of having high blood pressure at the start of ... with high levels of fitness. Of the more than ...
(Date:12/19/2014)... (HealthDay News) -- Traveling through the same U.S. airport ... three others within a four-hour time span, illustrating just ... shows. "The exposures in this report were not ... international terminal, highlighting the fact that measles is highly ... infectious disease specialist at the U.S. Centers for Disease ...
(Date:12/17/2014)... Unidesk Corporation today announced that the ... its inaugural class in August 2013, has successfully ... bring your own device (BYOD) and deliver a ... solution, comprised of Citrix XenDesktop and ... storage infrastructure and Unidesk virtual desktop ...
(Date:12/17/2014)... December 17, 2014 No matter how ... able to eradicate the head louse parasite—a common childhood ... parents. Each year between six and twelve million individuals ... Miami-based lice removal treatment company comes to the rescue, ... environmentally friendly. With its track record of customer service, ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... last, even if weight comes back , , TUESDAY, Aug. 12 ... weight soon after their diagnosis gain better control of their ... if they regain that weight. , "If you lose weight ... of blood pressure and glycemic control that extend even beyond ...
... Aug. 12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... The net loss for the second quarter ended June ... same period in 2007. The net,loss for the first six ... the first six months of 2007. As of June 30, ...
... dermatologists will offer free skin screenings in first-ever, outreach for Pilot Pen ... ... women, NEW HAVEN, Conn., Aug. 12 ... the,Women,s Dermatologic Society (WDS) will jump into the popular arena of,professional tennis ...
... - Over 1,000 eye care practices participating in nationwide ... conjunction with Back to,School time, Optos and over 1,000 ... schedule a comprehensive eye exam that includes,the optomap(R) Retinal ... learning is through vision, it is vital that children ...
... will host the first http://www.diahome.org/DIAHOME/Education/FindEducationalOffering.aspx?productID=16917&eventType=Meeting ... , ... ... August 12, 2008 -- The Drug Information ...
... healthcare staffing companies has launched a new website dedicated to ... Solutions is also unveiling a new Client Management brand to ... ... Omaha, NE (PRWEB) August 12, 2008 -- ...
Cached Medicine News:Health News:Weight Loss After Diabetes Diagnosis Offers Big Benefits: Study 2Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 2Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 3Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 4Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 5Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 6Health News:Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U.S. Open 2Health News:Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U.S. Open 3Health News:Optos Encourages Parents to Get Back to School Eye Exams for Their Children 2Health News:DIA Innovation Forum to Highlight Latest Initiatives in Research & Development in the EU 2Health News:Medical Solutions Announces the Launch of its New Client Management Website and Brand 2Health News:Medical Solutions Announces the Launch of its New Client Management Website and Brand 3
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
... With its simplified operations, the ... patient, clinic or satellite lab testing. ... offers multi-language software. Built on ... technology, the KX-21N features a completely ...
... The Integrity family of pacemakers ... and truly automatic devices in today's ... combination of automated features and diagnostic ... popular and proven Affinity pacemakers platform. ...
Medicine Products: